Prophylactic laser versus continued surveillance after initial bevacizumab treatment for retinopathy of prematurity.
Publication
, Journal Article
Hong, GJ; Stinnett, SS; Freedman, SF; Wallace, DK; Prakalapakorn, SG
Published in: J AAPOS
June 2021
Guidelines on managing infants after initial anti-vascular endothelial growth factor (VEGF) treatment (eg, bevacizumab) for retinopathy of prematurity (ROP) are limited. We found that following initial bevacizumab treatment for ROP, prophylactically lasering infant eyes before hospital discharge reduced the number and duration of outpatient ROP screening examinations compared with following infants, per current United States (US) ROP screening guidelines.
Duke Scholars
Published In
J AAPOS
DOI
EISSN
1528-3933
Publication Date
June 2021
Volume
25
Issue
3
Start / End Page
177 / 180
Location
United States
Related Subject Headings
- Vascular Endothelial Growth Factor A
- Retinopathy of Prematurity
- Ophthalmology & Optometry
- Lasers
- Laser Coagulation
- Intravitreal Injections
- Infant, Newborn
- Infant
- Humans
- Gestational Age
Citation
APA
Chicago
ICMJE
MLA
NLM
Hong, G. J., Stinnett, S. S., Freedman, S. F., Wallace, D. K., & Prakalapakorn, S. G. (2021). Prophylactic laser versus continued surveillance after initial bevacizumab treatment for retinopathy of prematurity. J AAPOS, 25(3), 177–180. https://doi.org/10.1016/j.jaapos.2021.02.002
Hong, Gloria J., Sandra S. Stinnett, Sharon F. Freedman, David K. Wallace, and S Grace Prakalapakorn. “Prophylactic laser versus continued surveillance after initial bevacizumab treatment for retinopathy of prematurity.” J AAPOS 25, no. 3 (June 2021): 177–80. https://doi.org/10.1016/j.jaapos.2021.02.002.
Hong GJ, Stinnett SS, Freedman SF, Wallace DK, Prakalapakorn SG. Prophylactic laser versus continued surveillance after initial bevacizumab treatment for retinopathy of prematurity. J AAPOS. 2021 Jun;25(3):177–80.
Hong, Gloria J., et al. “Prophylactic laser versus continued surveillance after initial bevacizumab treatment for retinopathy of prematurity.” J AAPOS, vol. 25, no. 3, June 2021, pp. 177–80. Pubmed, doi:10.1016/j.jaapos.2021.02.002.
Hong GJ, Stinnett SS, Freedman SF, Wallace DK, Prakalapakorn SG. Prophylactic laser versus continued surveillance after initial bevacizumab treatment for retinopathy of prematurity. J AAPOS. 2021 Jun;25(3):177–180.
Published In
J AAPOS
DOI
EISSN
1528-3933
Publication Date
June 2021
Volume
25
Issue
3
Start / End Page
177 / 180
Location
United States
Related Subject Headings
- Vascular Endothelial Growth Factor A
- Retinopathy of Prematurity
- Ophthalmology & Optometry
- Lasers
- Laser Coagulation
- Intravitreal Injections
- Infant, Newborn
- Infant
- Humans
- Gestational Age